Study of high-risk kidney cancer patients
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at patients with kidney cancer that hasn't spread and is considered high-risk. It uses a registry to learn more about these patients to improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older).
- You have been diagnosed with kidney cancer (renal cell carcinoma) that is localized or has not spread beyond the kidney, and is considered high-risk.
- You were included in the UroCCR registry between January 1, 2014, and December 31, 2023.
- You gave consent to participate in the UroCCR and UroCCR-Chain registries.
- You do not have cancer that has spread to other parts of the body (metastatic disease).
- You do not have inherited (hereditary) kidney cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry study collects information from people with different types of advanced or high-risk urologic cancers. It helps doctors learn more about how these cancers are treated in real life.
This study enrolls people newly diagnosed with kidney cancer (including when it has spread) to help build research resources for future kidney cancer care. If you qualify, your information may be used to better understand outcomes and improve treatments.
This trial studies how people with kidney cancer decide to join clinical studies. It looks at trends in participation to help make future studies better.
This study is testing a new scoring system to see if it can help predict the risk of cancer coming back in people with stage III clear cell kidney cancer. If you qualify, the study team will use your medical information to see if this scoring system could help guide future treatment decisions.
This trial tests a combination of three medicines—pembrolizumab (a drug that helps your immune system fight cancer), belzutifan, and lenvatinib (drugs that slow tumor growth)—in patients with early-stage kidney cancer who are candidates for surgery. The goal is to see if this combination can improve outcomes before or alongside surgery.
This study looks at whether people with metastatic kidney cancer can be managed with standard immune-based treatment and then have their main kidney tumor removed. It is meant for people who can have surgery and whose cancer has not grown at the time this approach is considered.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.